BridgeBio News and Activities

BridgeBio is one of the...

• Russell 3000;
• TOB Iconic 10,000.

BridgeBio is a company listed under the stock ticker BBIO (US).

Acquisition, funding and merger involving BridgeBio.

• BridgeBio has just announced a $1,000 Million fundraising (posted on July 2 2026).

View the org chart displaying its 60 main executives

Most searched biographies at BridgeBio

• Neil Kumar, Chief Executive Officer and Director
• Andrew Lo, Independent Director
• Andrea Ellis, Director

Popular executive movements at BridgeBio

• Danny Scott has joined the company as Director of Training and Development  (posted on June 29 2026).
• Maggie Sweeney has joined the company as Senior Director, Clinical Quality and Compliance  (posted on May 6 2026).
• Julie Miller Everett, who was Chief Business Officer, is promoted to Chief Operating Officer, Skeletal Dysplasias  (posted on April 23 2026).

Click here to view some more movements at BridgeBio

Create your alert
to follow the executive moves at BridgeBio.

BridgeBio has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by BridgeBio

• Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - BridgeBio
• Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients - BridgeBio
• Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months - BridgeBio
• BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia - BridgeBio
• BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - BridgeBio
• BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management - BridgeBio
• BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - BridgeBio
• BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio
• BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events - BridgeBio
• BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) - BridgeBio
• View more press releases Close

Social media about BridgeBio

• BridgeBio on Wikipedia, Google News & Yahoo Finance
• BridgeBio on LinkedIn, X (Twitter) & YouTube